{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-001495","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.320326+00:00","generated_at":"2026-05-16T11:42:30.375855+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Tango Therapeutics appoints Sung H. Lee to Board; grants option for 60k shares at $8.93","bullets":["Board expanded to 8; Lee appointed as Class I director, term until 2028 annual meeting.","Lee to receive stock option for 60,000 shares at $8.93, vesting monthly over 3 years.","Lee to receive RSU for 10,000 shares vesting annually over 3 years; $40k annual retainer.","Lee is EVP & CFO at Cytokinetics, previously CFO at Vir, MorphoSys, Sangamo; 20+ yrs finance experience.","CEO says Lee's expertise will support lead program vopimetostat in registrational studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-001495","json":"https://secwatch.observer/filing/0001193125-26-001495.json","markdown":"https://secwatch.observer/filing/0001193125-26-001495.md","text":"https://secwatch.observer/filing/0001193125-26-001495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526001495/0001193125-26-001495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526001495/d44532d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:42:30.375855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}